一位患有局部浸润性乳腺癌的年轻女性在孕早期使用曲妥珠单抗的情况
Trastuzumab Exposure in Early Pregnancy for a Young Lady With Locally Invasive Breast Cancer.
作者信息
Pianca Natasha, Shafiei Mohsen, George Mathew
机构信息
Department of Medical Oncology, Northwest Regional Cancer Centre, Tamworth, Australia.
出版信息
World J Oncol. 2015 Jun;6(3):381-382. doi: 10.14740/wjon919w. Epub 2015 Jun 12.
Abstract
Due to the lack of literature on the effects of trastuzumab in pregnancy, an interest has been taken in a patient that incidentally became pregnant while on adjuvant treatment in the first trimester following diagnosis of locally advanced breast cancer.
摘要
由于缺乏关于曲妥珠单抗在妊娠期间作用的文献，我们对一名在诊断为局部晚期乳腺癌后的孕早期接受辅助治疗时意外怀孕的患者产生了兴趣。
相似文献
1
Trastuzumab Exposure in Early Pregnancy for a Young Lady With Locally Invasive Breast Cancer.一位患有局部浸润性乳腺癌的年轻女性在孕早期使用曲妥珠单抗的情况
World J Oncol. 2015 Jun;6(3):381-382. doi: 10.14740/wjon919w. Epub 2015 Jun 12.
2
Trastuzumab in the Treatment of Pregnant Breast Cancer Patients - an Overview of the Literature.曲妥珠单抗治疗妊娠乳腺癌患者——文献综述
Geburtshilfe Frauenheilkd. 2019 Jun;79(6):618-625. doi: 10.1055/a-0880-9295. Epub 2019 Jun 14.
3
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.曲妥珠单抗和/或拉帕替尼治疗人表皮生长因子受体 2 阳性早期乳腺癌患者的妊娠情况：NeoALTTO（BIG 1-06）和 ALTTO（BIG 2-06）试验分析。
Cancer. 2019 Jan 15;125(2):307-316. doi: 10.1002/cncr.31784. Epub 2018 Oct 18.
4
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.曲妥珠单抗新辅助化疗联合辅助曲妥珠单抗与单纯新辅助化疗治疗人表皮生长因子受体 2 阳性局部晚期乳腺癌患者（NOAH 试验）：一项具有平行人表皮生长因子受体 2 阴性队列的随机对照优效性试验。
Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.
5
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.局部晚期、炎症性或早期 HER2 阳性乳腺癌患者新辅助帕妥珠单抗和曲妥珠单抗的 5 年分析（NeoSphere）：一项多中心、开放性标签、2 期随机试验。
Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11.
6
Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.曲妥珠单抗在局部浸润性乳腺癌辅助治疗中的作用。
Am J Health Syst Pharm. 2006 Mar 15;63(6):527-33. doi: 10.2146/ajhp050400.
7
Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up.孕期使用曲妥珠单抗：局部晚期乳腺癌后的长期生存及婴儿长期随访
Anticancer Drugs. 2016 Apr;27(4):369-72. doi: 10.1097/CAD.0000000000000344.
8
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.曲妥珠单抗新辅助和辅助治疗人表皮生长因子受体 2 阳性局部晚期乳腺癌（NOAH）患者：一项随机对照优效试验的随访，该试验具有平行的人表皮生长因子受体 2 阴性队列。
Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20.
9
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.赫敏：一项随机2期试验，比较MM - 302联合曲妥珠单抗与医生选择的化疗方案联合曲妥珠单抗，用于治疗既往接受过治疗、未使用过蒽环类药物、HER2阳性、局部晚期/转移性乳腺癌患者。
BMC Cancer. 2016 Jun 3;16:352. doi: 10.1186/s12885-016-2385-z.
10
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
引用本文的文献
1
Trastuzumab administration during pregnancy: an update.怀孕期间曲妥珠单抗的使用：最新进展。
BMC Cancer. 2021 Apr 26;21(1):463. doi: 10.1186/s12885-021-08162-3.
2
Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis.曲妥珠单抗在妊娠期乳腺癌治疗中的应用：系统评价和荟萃分析。
BMC Womens Health. 2021 Apr 21;21(1):169. doi: 10.1186/s12905-021-01301-9.
本文引用的文献
1
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.曲妥珠单抗辅助治疗 HER2 阳性乳腺癌 2 年与 1 年的疗效对比（HERA）：一项开放标签、随机对照临床试验。
Lancet. 2013 Sep 21;382(9897):1021-8. doi: 10.1016/S0140-6736(13)61094-6. Epub 2013 Jul 18.
2
Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).HERA 试验（BIG 01-01）中接受曲妥珠单抗辅助治疗期间或之后妊娠的患者。
Breast Cancer Res Treat. 2012 May;133(1):387-91. doi: 10.1007/s10549-012-1996-6. Epub 2012 Feb 26.
3
Breast cancer and pregnancy: how safe is trastuzumab?
Nat Rev Clin Oncol. 2009 Jun;6(6):367-70. doi: 10.1038/nrclinonc.2009.48.
4
Treatment of breast cancer with trastuzumab during pregnancy.孕期使用曲妥珠单抗治疗乳腺癌。
J Clin Oncol. 2008 Mar 20;26(9):1567-9. doi: 10.1200/JCO.2008.16.0309.
5
Trastuzumab--mechanism of action and use in clinical practice.曲妥珠单抗——作用机制及临床应用
N Engl J Med. 2007 Jul 5;357(1):39-51. doi: 10.1056/NEJMra043186.
6
Effect of adjuvant trastuzumab on pregnancy.
J Clin Oncol. 2006 Jan 10;24(2):321-2. doi: 10.1200/JCO.2005.04.6607.
Zotero 插件